Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M379Revenue (TTM) $M22.0Net Margin (%)-313.0Altman Z-Score-7.7
Enterprise Value $M380EPS (TTM) $-0.9Operating Margin %-262.2Piotroski F-Score2
P/E(ttm)--Beneish M-Score-2.6Pre-tax Margin (%)-313.0Higher ROA y-yN
Price/Book95.210-y EBITDA Growth Rate %-7.2Quick Ratio1.2Cash flow > EarningsY
Price/Sales17.35-y EBITDA Growth Rate %-10.7Current Ratio1.3Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-63.7Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-219.1Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M73.8ROIC % (ttm)-329.0Gross Margin Increase y-yY

Gurus Latest Trades with BCRX

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
(Average)*
Current Price Change from Average Comment Current Shares

BCRX is held by these investors:



BCRX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
STAAB THOMAS R IISenior Vice President and CFO 2016-12-19Sell3,250$7.45-34.77view
Barnes Alane PVP, General Counsel & Corp Sec 2016-09-14Sell8,357$4.2713.82view
Babu Yarlagadda SSenior VP - Drug Discovery 2016-08-25Sell30,000$4.0619.7view
BAKER BROS. ADVISORS LP10% Owner 2016-08-16Sell4,046,590$5-2.8view
STAAB THOMAS R IISenior Vice President and CFO 2016-08-12Sell5,864$5.18-6.18view
STAAB THOMAS R IISenior Vice President and CFO 2016-08-09Sell14,577$4.439.71view
BAKER BROS. ADVISORS LP10% Owner 2016-02-05Buy45,000$6.33-23.22view
BAKER BROS. ADVISORS LP10% Owner 2016-02-04Buy207,715$6.43-24.42view
BAKER BROS. ADVISORS LP10% Owner 2016-01-28Buy88,345$6.95-30.07view
BAKER BROS. ADVISORS LP10% Owner 2016-01-22Buy106,800$7.28-33.24view

Quarterly/Annual Reports about BCRX:

News about BCRX:

Articles On GuruFocus.com
A Trump Presidency May Be Good for Biotech Dec 16 2016 
BioCryst Pharmaceuticals Inc. Reports Operating Results (10-K) Mar 15 2011 
BioCryst Pharmaceuticals Inc. Reports Operating Results (10-K/A) Jan 19 2011 
BioCryst Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 08 2010 
BioCryst Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 06 2010 
BioCryst Pharmaceuticals Inc. (BCRX) SR VP & CFO Stuart Grant sells 2,500 Shares Aug 06 2010 
BioCryst Pharmaceuticals Inc. (BCRX) SR VP & CFO Stuart Grant sells 1,250 Shares Jun 04 2010 
BioCryst Pharmaceuticals Inc. Reports Operating Results (10-Q) May 07 2010 
BioCryst Pharmaceuticals Inc. (BCRX) SR VP & CFO Stuart Grant sells 1,250 Shares May 05 2010 
BioCryst Pharmaceuticals Inc. (BCRX) SR VP & CFO Stuart Grant sells 38,553 Shares Apr 30 2010 

More From Other Websites
BioCryst Pill Prevents Swelling Attacks but Shares Fall on Competitive Concerns Feb 27 2017
Biotech Premarket Movers: BioCryst, Sangamo, Cempra Feb 27 2017
BioCryst Pharmaceuticals Stock Drops After Reporting 4Q Loss Feb 27 2017
BIOCRYST PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition,... Feb 27 2017
Q4 2016 BioCryst Pharmaceuticals Inc Earnings Release - Before Market Open Feb 27 2017
BioCryst reports 4Q loss Feb 27 2017
BioCryst reports 4Q loss Feb 27 2017
6:26 am BioCryst Pharma beats by $0.18, beats on revs; reports statistically significant and... Feb 27 2017
BioCryst Reports Fourth Quarter and Full Year 2016 Financial Results Feb 27 2017
BioCryst Reports Positive Interim Results from its APeX-1 Trial Feb 27 2017
Is the Options Market Predicting a Spike in BioCryst Pharmaceuticals (BCRX) Stock? Feb 17 2017
BioCryst Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : BCRX-US :... Feb 17 2017
Coverage initiated on BioCryst Pharma by Ladenburg Thalmann Feb 16 2017
BioCryst to Announce Fourth Quarter and Year End 2016 Financial Results February 27 Feb 15 2017
BioCryst Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : BCRX-US :... Jan 31 2017
BioCryst plans for European launch of injectable flu therapy Jan 30 2017
BIOCRYST PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Jan 30 2017
BioCryst Announces the Acceptance of Peramivir MAA Filing by the European Medicines Agency Jan 30 2017
Is the Options Market Predicting a Spike in BioCryst Pharmaceuticals (BCRX) Stock? Jan 25 2017
BioCryst Pharmaceuticals, Inc. – Value Analysis (NASDAQ:BCRX) : January 23, 2017 Jan 23 2017

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)